Samanta et al. reported that treatment of TNBC cells with carboplatin, doxorubicin, gemcitabine or paclitaxel promoted the enrichment of CD47+CD73+PDL1+ TNBC cells and promoted tumor immune evasion, which could be eliminated by inhibiting HIF [157]. This evidence concerns the gene CD47 and neoplasm.